Your browser doesn't support javascript.
loading
Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial.
de Crevoisier, Renaud; Bayar, Mohamed Amine; Pommier, Pascal; Muracciole, Xavier; Pêne, Françoise; Dudouet, Philippe; Latorzeff, Igor; Beckendorf, Véronique; Bachaud, Jean-Marc; Laplanche, Agnès; Supiot, Stéphane; Chauvet, Bruno; Nguyen, Tan-Dat; Bossi, Alberto; Créhange, Gilles; Lagrange, Jean Léon.
Afiliação
  • de Crevoisier R; Department of Radiotherapy, Centre Eugène Marquis, LTSI INSERM 1099, Rennes, France. Electronic address: r.de-crevoisier@rennes.unicancer.fr.
  • Bayar MA; Department of Biostatistics, Gustave-Roussy Institute, Villejuif, France; CESP, Faculté de médecine, Université Paris-Sud, Faculté de médecine, UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
  • Pommier P; Department of Radiotherapy, Léon Bérard Cancer Center, Lyon, France.
  • Muracciole X; Department of Radiotherapy, de la Timone Hospital, Marseille, France.
  • Pêne F; Department of Radiotherapy, Tenon Hospital, Paris, France; Clinique Hartmann, Levallois-Perret, France.
  • Dudouet P; Department of Radiotherapy, Clinique du Pont de Chaume Clinic, Montauban, France.
  • Latorzeff I; Department of Radiotherapy, Clinique Pasteur, Toulouse, France.
  • Beckendorf V; Department of Radiotherapy, Alexis Vautrin Center, Vandoeuvre les Nancy, France.
  • Bachaud JM; Department of Radiotherapy, Institut Claudius Regaud, Toulouse, France.
  • Laplanche A; Department of Biostatistics, Gustave-Roussy Institute, Villejuif, France.
  • Supiot S; Department of Radiotherapy, Institut de Cancérologie de l'Ouest, Saint Herblain, France.
  • Chauvet B; Department of Radiotherapy, Sainte Catherine Institute, Avignon, France.
  • Nguyen TD; Department of Radiotherapy, Jean-Godinot Institute, Reims, France.
  • Bossi A; Department of Radiotherapy, Gustave-Roussy Institute, Villejuif, France.
  • Créhange G; Department of Radiotherapy, Georges-François Leclerc Center, Dijon, France.
  • Lagrange JL; Department of Radiotherapy, APHP Henri Mondor Hospital, UPEC Créteil, France.
Int J Radiat Oncol Biol Phys ; 102(5): 1420-1429, 2018 12 01.
Article em En | MEDLINE | ID: mdl-30071296
ABSTRACT

PURPOSE:

The optimal frequency of prostate cancer image guided radiation therapy (IGRT) has not yet been clearly identified. This study sought to compare the safety and efficacy of daily versus weekly IGRT. MATERIALS AND

METHODS:

This phase 3 randomized trial recruited patients with N0 localized prostate cancer. The total IGRT doses in the prostate ranged from 70 Gy to 80 Gy, sparing the lymph nodes. Patients were randomly assigned (11) to 2 prostate IGRT frequency groups daily and weekly (ie, on days 1, 2, and 3 and then weekly). The primary outcome was 5-year recurrence-free survival. Secondary outcomes included overall survival and toxicity. Post hoc analyses included biochemical progression-free interval, clinical progression-free interval, and other cancer-free interval.

RESULTS:

Between June 2007 and November 2012, 470 men from 21 centers were randomized into the 2 groups. Median follow-up was 4.1 years. There was no statistically significant difference in recurrence-free survival between the groups (hazard ratio [HR] = 0.81; P = .330). Overall survival was worse in the daily group than in the weekly group (HR = 2.12 [95% confidence interval (CI), 1.03-4.37]; P = .042). Acute rectal bleeding (grade ≥1) was significantly lower in the daily group (6%) (n = 14) than in the weekly group (11%) (n = 26) (P = .014). Late rectal toxicity (grade ≥1) was significantly lower in the daily group (HR = 0.71 [95% CI, 0.53-0.96]; P = .027). Biochemical progression-free interval (HR = 0.45 [95% CI, 0.25 - 0.80]; P = .007) and clinical progression-free interval (HR = 0.50 [95% CI, 0.24-1.02]; P = .057) were better in the daily group, whereas other cancer-free interval was worse in the daily group (HR = 2.21 [95% CI, 1.10-4.44]; P = .026).

CONCLUSIONS:

Compared with weekly control, daily IGRT control in prostate cancer significantly improves biochemical progression-free and clinical progression-free interval, and rectal toxicity.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Radioterapia Guiada por Imagem Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Radioterapia Guiada por Imagem Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article